The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A first-in-human (FIH) phase I study of SAR125844, a novel selective MET kinase inhibitor, in patients (pts) with advanced solid tumors: Dose escalation results.
Eric Angevin
No relevant relationships to disclose
Gianluca Spitaleri
No relevant relationships to disclose
Antoine Hollebecque
No relevant relationships to disclose
Tommaso De Pas
No relevant relationships to disclose
Jean-Charles Soria
No relevant relationships to disclose
Marzia Harnois
Employment or Leadership Position - Sanofi
Florent Mazuir
Employment or Leadership Position - Sanofi
Sylvie Assadourian
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Filippo De Marinis
No relevant relationships to disclose